Engineered antibodies market to be worth $5.7 billion by 2023: report

5 September 2013

The market for engineered antibodies is forecast to reach a value of $5.7 billion by 2023, according to a new report for Root Analysis, titled Fc Protein GLycoengineered Antibodies Market, 2013-2023.

The report provides an extensive study of this emerging field, including detailed sales forecast (till 2023) of the following 10 molecules in Phase II / III clinical trials:

1. Mogamulizumab/POTELIGEO/KW-0761/AMG761
2. Obinutuzumab/GA101
3. Benralizumab/MEDI-563
4. MEDI-551
5. Ecromeximab/KW-2871
6. Roledumab/LFB-r593
7. Ublituximab/LFB-r603/TGT-1101
8. Ocaratuzumab/AME-133v
9. Margetuximab/MGAH22
10. XmAb5574/MOR208

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology